You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePentolinium
Accession NumberDB01090  (APRD00038)
TypeSmall Molecule
GroupsApproved
DescriptionA nicotinic antagonist that has been used as a ganglionic blocking agent in hypertension. [PubChem]
Structure
Thumb
Synonyms
Pentolineum
Pentolonium
Pentolonum
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AnsolysenNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Pentolinium tartrate
52-62-0
Thumb
  • InChI Key: HSMKTIKKPMTUQH-WBPXWQEISA-L
  • Monoisotopic Mass: 538.273774818
  • Average Mass: 538.5858
DBSALT000236
Categories
UNIIULL76WPU5X
CAS number144-44-5
WeightAverage: 240.428
Monoisotopic: 240.256549034
Chemical FormulaC15H32N2
InChI KeyInChIKey=XSBSKEQEUFOSDD-UHFFFAOYSA-N
InChI
InChI=1S/C15H32N2/c1-16(12-6-7-13-16)10-4-3-5-11-17(2)14-8-9-15-17/h3-15H2,1-2H3/q+2
IUPAC Name
1-methyl-1-[5-(1-methylpyrrolidin-1-ium-1-yl)pentyl]pyrrolidin-1-ium
SMILES
C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-alkylpyrrolidines. These are compounds containing a pyrrolidine moiety that is substituted at the N1-position with an alkyl group. Pyrrolidine is a five-membered saturated aliphatic heterocycle with one nitrogen atom and four carbon atoms.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyrrolidines
Sub ClassN-alkylpyrrolidines
Direct ParentN-alkylpyrrolidines
Alternative Parents
Substituents
  • N-alkylpyrrolidine
  • Quaternary ammonium salt
  • Azacycle
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Organic cation
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationUsed to produce controlled hypotension during surgical procedures and in hypertensive crises.
PharmacodynamicsPentolinium acts as a ganglionic blocking agent. Pentolinium inhibits release of adrenaline and noradrenaline from adrenergic nerves. It is used as an antihypertensive, and can be administered orally, intramuscularly, and subcutaneously.
Mechanism of actionPentolinium binds to the nicotinic (ganglion) acetylcholine receptor. This receptor/channel is permeable to a range of divalent cations including calcium, the influx of which may activate a potassium current which hyperpolarizes the cell membrane. Blockage of the receptor leads to smooth muscle relaxation and vasodilaton.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityOral, mouse: LD50 = 512 mg/kg; Oral, rat: LD50 = 890 mg/kg.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9722
Blood Brain Barrier+0.9922
Caco-2 permeable+0.6627
P-glycoprotein substrateSubstrate0.5993
P-glycoprotein inhibitor INon-inhibitor0.9697
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterInhibitor0.6294
CYP450 2C9 substrateNon-substrate0.8782
CYP450 2D6 substrateNon-substrate0.607
CYP450 3A4 substrateNon-substrate0.5941
CYP450 1A2 substrateNon-inhibitor0.9834
CYP450 2C9 inhibitorNon-inhibitor0.9533
CYP450 2D6 inhibitorNon-inhibitor0.9312
CYP450 2C19 inhibitorNon-inhibitor0.9348
CYP450 3A4 inhibitorNon-inhibitor0.9943
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9857
Ames testNon AMES toxic0.758
CarcinogenicityNon-carcinogens0.8783
BiodegradationReady biodegradable0.7183
Rat acute toxicity2.7632 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7283
hERG inhibition (predictor II)Non-inhibitor0.7476
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point213 °C (tartrate salt)Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.16e-05 mg/mLALOGPS
logP-2.3ALOGPS
logP-6.3ChemAxon
logS-7.4ALOGPS
Physiological Charge2ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity99.03 m3·mol-1ChemAxon
Polarizability31.36 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (61.6 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe therapeutic efficacy of Pentolinium can be decreased when used in combination with 1,10-Phenanthroline.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Pentolinium.
AcebutololPentolinium may increase the hypotensive activities of Acebutolol.
AclidiniumAclidinium may increase the anticholinergic activities of Pentolinium.
AclidiniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Aclidinium.
AlfentanilThe risk or severity of adverse effects can be increased when Pentolinium is combined with Alfentanil.
AlfuzosinAlfuzosin may increase the hypotensive activities of Pentolinium.
AliskirenPentolinium may increase the hypotensive activities of Aliskiren.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Pentolinium is combined with Alphacetylmethadol.
AlprenololAlprenolol may increase the hypotensive activities of Pentolinium.
AmbenoniumThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Ambenonium.
AmbrisentanPentolinium may increase the hypotensive activities of Ambrisentan.
AmifostinePentolinium may increase the hypotensive activities of Amifostine.
AmlodipineAmlodipine may increase the hypotensive activities of Pentolinium.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Pentolinium.
AtenololAtenolol may increase the hypotensive activities of Pentolinium.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Pentolinium.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Pentolinium.
BenactyzineThe risk or severity of adverse effects can be increased when Pentolinium is combined with Benactyzine.
BenazeprilBenazepril may increase the hypotensive activities of Pentolinium.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Pentolinium.
BenmoxinBenmoxin may increase the hypotensive activities of Pentolinium.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Pentolinium.
BepridilPentolinium may increase the hypotensive activities of Bepridil.
BetaxololBetaxolol may increase the hypotensive activities of Pentolinium.
BethanidineBethanidine may increase the hypotensive activities of Pentolinium.
BezitramideThe risk or severity of adverse effects can be increased when Pentolinium is combined with Bezitramide.
BimatoprostBimatoprost may increase the hypotensive activities of Pentolinium.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Pentolinium.
BisoprololBisoprolol may increase the hypotensive activities of Pentolinium.
BosentanBosentan may increase the hypotensive activities of Pentolinium.
Botulinum Toxin Type APentolinium may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BPentolinium may increase the anticholinergic activities of Botulinum Toxin Type B.
BretyliumPentolinium may increase the hypotensive activities of Bretylium.
BrimonidinePentolinium may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Pentolinium.
BupranololPentolinium may increase the hypotensive activities of Bupranolol.
BuprenorphineThe risk or severity of adverse effects can be increased when Pentolinium is combined with Buprenorphine.
ButorphanolThe risk or severity of adverse effects can be increased when Pentolinium is combined with Butorphanol.
CandesartanCandesartan may increase the hypotensive activities of Pentolinium.
CandoxatrilCandoxatril may increase the hypotensive activities of Pentolinium.
CaptoprilPentolinium may increase the hypotensive activities of Captopril.
CarfentanilThe risk or severity of adverse effects can be increased when Pentolinium is combined with Carfentanil.
CaroxazoneCaroxazone may increase the hypotensive activities of Pentolinium.
CarteololCarteolol may increase the hypotensive activities of Pentolinium.
CarvedilolPentolinium may increase the hypotensive activities of Carvedilol.
CeliprololPentolinium may increase the hypotensive activities of Celiprolol.
ChlorothiazideChlorothiazide may increase the hypotensive activities of Pentolinium.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Pentolinium is combined with Chlorphenoxamine.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Pentolinium.
CilazaprilPentolinium may increase the hypotensive activities of Cilazapril.
CimetropiumPentolinium may increase the anticholinergic activities of Cimetropium.
ClonidineClonidine may increase the hypotensive activities of Pentolinium.
CodeineThe risk or severity of adverse effects can be increased when Pentolinium is combined with Codeine.
CoumaphosThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Coumaphos.
CryptenamineCryptenamine may increase the hypotensive activities of Pentolinium.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Pentolinium.
CyclothiazideCyclothiazide may increase the hypotensive activities of Pentolinium.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Pentolinium.
DebrisoquinPentolinium may increase the hypotensive activities of Debrisoquin.
DecamethoniumThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Decamethonium.
DemecariumThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Demecarium.
DeserpidinePentolinium may increase the hypotensive activities of Deserpidine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Pentolinium.
DexetimideThe risk or severity of adverse effects can be increased when Pentolinium is combined with Dexetimide.
DextromoramideThe risk or severity of adverse effects can be increased when Pentolinium is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Pentolinium is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Pentolinium is combined with Dezocine.
DiazoxideDiazoxide may increase the hypotensive activities of Pentolinium.
DichlorvosThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Dichlorvos.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Pentolinium.
DihydrocodeineThe risk or severity of adverse effects can be increased when Pentolinium is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Pentolinium is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Pentolinium is combined with Dihydromorphine.
DiltiazemDiltiazem may increase the hypotensive activities of Pentolinium.
DiphenoxylateThe risk or severity of adverse effects can be increased when Pentolinium is combined with Diphenoxylate.
DonepezilThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Donepezil.
DorzolamideDorzolamide may increase the hypotensive activities of Pentolinium.
DoxazosinDoxazosin may increase the hypotensive activities of Pentolinium.
DPDPEThe risk or severity of adverse effects can be increased when Pentolinium is combined with DPDPE.
DronabinolPentolinium may increase the tachycardic activities of Dronabinol.
EchothiophateThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Echothiophate.
EdrophoniumThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Edrophonium.
EfonidipinePentolinium may increase the hypotensive activities of Efonidipine.
EluxadolinePentolinium may increase the constipating activities of Eluxadoline.
EnalaprilEnalapril may increase the hypotensive activities of Pentolinium.
EnalaprilatPentolinium may increase the hypotensive activities of Enalaprilat.
EpoprostenolPentolinium may increase the hypotensive activities of Epoprostenol.
EprosartanEprosartan may increase the hypotensive activities of Pentolinium.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Pentolinium.
EthylmorphineThe risk or severity of adverse effects can be increased when Pentolinium is combined with Ethylmorphine.
EtorphineThe risk or severity of adverse effects can be increased when Pentolinium is combined with Etorphine.
FelodipineFelodipine may increase the hypotensive activities of Pentolinium.
FenoldopamFenoldopam may increase the hypotensive activities of Pentolinium.
FentanylThe risk or severity of adverse effects can be increased when Pentolinium is combined with Fentanyl.
FenthionThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Fenthion.
FesoterodineThe risk or severity of adverse effects can be increased when Pentolinium is combined with Fesoterodine.
FosinoprilFosinopril may increase the hypotensive activities of Pentolinium.
FurazolidoneFurazolidone may increase the hypotensive activities of Pentolinium.
GalantamineThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Pentolinium.
Ginkgo bilobaThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Ginkgo biloba.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Pentolinium is combined with Glucagon recombinant.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Pentolinium.
GlycopyrroniumPentolinium may increase the anticholinergic activities of Glycopyrronium.
GuanabenzGuanabenz may increase the hypotensive activities of Pentolinium.
GuanadrelGuanadrel may increase the hypotensive activities of Pentolinium.
GuanethidinePentolinium may increase the hypotensive activities of Guanethidine.
GuanfacineGuanfacine may increase the hypotensive activities of Pentolinium.
HeroinThe risk or severity of adverse effects can be increased when Pentolinium is combined with Heroin.
HexamethoniumPentolinium may increase the hypotensive activities of Hexamethonium.
HomatropineThe risk or severity of adverse effects can be increased when Pentolinium is combined with Homatropine.
Huperzine AThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Huperzine A.
HydracarbazineHydracarbazine may increase the hypotensive activities of Pentolinium.
HydralazinePentolinium may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Pentolinium.
HydrocodoneThe risk or severity of adverse effects can be increased when Pentolinium is combined with Hydrocodone.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Pentolinium.
HydromorphoneThe risk or severity of adverse effects can be increased when Pentolinium is combined with Hydromorphone.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Pentolinium.
IloprostIloprost may increase the hypotensive activities of Pentolinium.
IndapamideIndapamide may increase the hypotensive activities of Pentolinium.
IndenololPentolinium may increase the hypotensive activities of Indenolol.
IndoraminPentolinium may increase the hypotensive activities of Indoramin.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pentolinium.
IproclozideIproclozide may increase the hypotensive activities of Pentolinium.
IproniazidIproniazid may increase the hypotensive activities of Pentolinium.
IrbesartanIrbesartan may increase the hypotensive activities of Pentolinium.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Pentolinium.
IsoflurophateThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Isoflurophate.
IsradipineIsradipine may increase the hypotensive activities of Pentolinium.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Pentolinium.
KetobemidoneThe risk or severity of adverse effects can be increased when Pentolinium is combined with Ketobemidone.
LabetalolLabetalol may increase the hypotensive activities of Pentolinium.
LacidipinePentolinium may increase the hypotensive activities of Lacidipine.
LatanoprostLatanoprost may increase the hypotensive activities of Pentolinium.
LercanidipineLercanidipine may increase the hypotensive activities of Pentolinium.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Pentolinium is combined with Levomethadyl Acetate.
LevorphanolThe risk or severity of adverse effects can be increased when Pentolinium is combined with Levorphanol.
LisinoprilLisinopril may increase the hypotensive activities of Pentolinium.
LofentanilThe risk or severity of adverse effects can be increased when Pentolinium is combined with Lofentanil.
LofexidinePentolinium may increase the hypotensive activities of Lofexidine.
LosartanLosartan may increase the hypotensive activities of Pentolinium.
MacitentanPentolinium may increase the hypotensive activities of Macitentan.
MalathionThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Malathion.
ManidipinePentolinium may increase the hypotensive activities of Manidipine.
MebanazineMebanazine may increase the hypotensive activities of Pentolinium.
MecamylamineMecamylamine may increase the hypotensive activities of Pentolinium.
MefloquineThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Mefloquine.
MemantineThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Memantine.
MethadoneThe risk or severity of adverse effects can be increased when Pentolinium is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Pentolinium is combined with Methadyl Acetate.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Pentolinium.
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Pentolinium.
MethyldopaMethyldopa may increase the hypotensive activities of Pentolinium.
Methylene blueMethylene blue may increase the hypotensive activities of Pentolinium.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Pentolinium.
MetipranololPentolinium may increase the hypotensive activities of Metipranolol.
MetixeneThe risk or severity of adverse effects can be increased when Pentolinium is combined with Metixene.
MetolazoneMetolazone may increase the hypotensive activities of Pentolinium.
MetoprololMetoprolol may increase the hypotensive activities of Pentolinium.
MianserinMianserin may increase the anticholinergic activities of Pentolinium.
MibefradilPentolinium may increase the hypotensive activities of Mibefradil.
MinaprineThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Minaprine.
MinoxidilMinoxidil may increase the hypotensive activities of Pentolinium.
MirabegronThe risk or severity of adverse effects can be increased when Pentolinium is combined with Mirabegron.
MoclobemideMoclobemide may increase the hypotensive activities of Pentolinium.
MoexiprilMoexipril may increase the hypotensive activities of Pentolinium.
MolsidomineMolsidomine may increase the hypotensive activities of Pentolinium.
MorphineThe risk or severity of adverse effects can be increased when Pentolinium is combined with Morphine.
MoxonidinePentolinium may increase the hypotensive activities of Moxonidine.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when Pentolinium is combined with N-butylscopolammonium bromide.
NabilonePentolinium may increase the tachycardic activities of Nabilone.
NadololPentolinium may increase the hypotensive activities of Nadolol.
NalbuphineThe risk or severity of adverse effects can be increased when Pentolinium is combined with Nalbuphine.
NebivololPentolinium may increase the hypotensive activities of Nebivolol.
NeostigmineThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Neostigmine.
NialamideNialamide may increase the hypotensive activities of Pentolinium.
NicardipineNicardipine may increase the hypotensive activities of Pentolinium.
NicorandilPentolinium may increase the hypotensive activities of Nicorandil.
NiguldipinePentolinium may increase the hypotensive activities of Niguldipine.
NilvadipinePentolinium may increase the hypotensive activities of Nilvadipine.
NimodipineNimodipine may increase the hypotensive activities of Pentolinium.
NisoldipineNisoldipine may increase the hypotensive activities of Pentolinium.
NitrendipineNitrendipine may increase the hypotensive activities of Pentolinium.
NitroprussideNitroprusside may increase the hypotensive activities of Pentolinium.
NormethadoneThe risk or severity of adverse effects can be increased when Pentolinium is combined with Normethadone.
NVA237The risk or severity of adverse effects can be increased when Pentolinium is combined with NVA237.
ObinutuzumabPentolinium may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Pentolinium.
OlmesartanOlmesartan may increase the hypotensive activities of Pentolinium.
OmapatrilatOmapatrilat may increase the hypotensive activities of Pentolinium.
OpiumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Opium.
OrphenadrineThe risk or severity of adverse effects can be increased when Pentolinium is combined with Orphenadrine.
OxprenololPentolinium may increase the hypotensive activities of Oxprenolol.
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Pentolinium.
OxycodoneThe risk or severity of adverse effects can be increased when Pentolinium is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Pentolinium is combined with Oxymorphone.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Pentolinium.
PancuroniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Pancuronium.
PargylinePentolinium may increase the hypotensive activities of Pargyline.
PenbutololPentolinium may increase the hypotensive activities of Penbutolol.
PentazocineThe risk or severity of adverse effects can be increased when Pentolinium is combined with Pentazocine.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Pentolinium.
PerindoprilPerindopril may increase the hypotensive activities of Pentolinium.
PethidineThe risk or severity of adverse effects can be increased when Pentolinium is combined with Pethidine.
PhenelzinePhenelzine may increase the hypotensive activities of Pentolinium.
PheniprazinePheniprazine may increase the hypotensive activities of Pentolinium.
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Pentolinium.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Pentolinium.
PhentolaminePhentolamine may increase the hypotensive activities of Pentolinium.
PhysostigmineThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Physostigmine.
PinacidilPentolinium may increase the hypotensive activities of Pinacidil.
PindololPindolol may increase the hypotensive activities of Pentolinium.
PipecuroniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Pipecuronium.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Pentolinium.
PirlindolePirlindole may increase the hypotensive activities of Pentolinium.
PivhydrazinePivhydrazine may increase the hypotensive activities of Pentolinium.
PolythiazidePentolinium may increase the hypotensive activities of Polythiazide.
Potassium ChloridePentolinium may increase the ulcerogenic activities of Potassium Chloride.
PramlintidePramlintide may increase the anticholinergic activities of Pentolinium.
PrazosinPrazosin may increase the hypotensive activities of Pentolinium.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Pentolinium.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Pentolinium.
PropranololPropranolol may increase the hypotensive activities of Pentolinium.
PyridostigmineThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Pyridostigmine.
QuinaprilQuinapril may increase the hypotensive activities of Pentolinium.
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Pentolinium.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Pentolinium.
QuinineQuinine may increase the hypotensive activities of Pentolinium.
RamiprilRamipril may increase the hypotensive activities of Pentolinium.
RamosetronPentolinium may increase the constipating activities of Ramosetron.
RasagilineRasagiline may increase the hypotensive activities of Pentolinium.
RemifentanilThe risk or severity of adverse effects can be increased when Pentolinium is combined with Remifentanil.
RemikirenRemikiren may increase the hypotensive activities of Pentolinium.
RescinnaminePentolinium may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Pentolinium.
RiociguatPentolinium may increase the hypotensive activities of Riociguat.
RituximabPentolinium may increase the hypotensive activities of Rituximab.
RivastigmineThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Rivastigmine.
SafrazineSafrazine may increase the hypotensive activities of Pentolinium.
SaprisartanPentolinium may increase the hypotensive activities of Saprisartan.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pentolinium.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Pentolinium is combined with Scopolamine butylbromide.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Pentolinium.
SelegilineSelegiline may increase the hypotensive activities of Pentolinium.
SelexipagPentolinium may increase the hypotensive activities of Selexipag.
SildenafilSildenafil may increase the antihypertensive activities of Pentolinium.
SitaxentanPentolinium may increase the hypotensive activities of Sitaxentan.
SolifenacinThe risk or severity of adverse effects can be increased when Pentolinium is combined with Solifenacin.
SpiraprilPentolinium may increase the hypotensive activities of Spirapril.
SufentanilThe risk or severity of adverse effects can be increased when Pentolinium is combined with Sufentanil.
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Pentolinium.
TacrineThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Tacrine.
TadalafilTadalafil may increase the antihypertensive activities of Pentolinium.
TapentadolThe risk or severity of adverse effects can be increased when Pentolinium is combined with Tapentadol.
TelmisartanTelmisartan may increase the hypotensive activities of Pentolinium.
TemocaprilPentolinium may increase the hypotensive activities of Temocapril.
TerlipressinPentolinium may increase the hypotensive activities of Terlipressin.
TibolonePentolinium may increase the hypotensive activities of Tibolone.
TicrynafenPentolinium may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Pentolinium.
TiotropiumPentolinium may increase the anticholinergic activities of Tiotropium.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Pentolinium.
TolazolineTolazoline may increase the hypotensive activities of Pentolinium.
ToloxatoneToloxatone may increase the hypotensive activities of Pentolinium.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Pentolinium.
TopiramateThe risk or severity of adverse effects can be increased when Pentolinium is combined with Topiramate.
TorasemideTorasemide may increase the hypotensive activities of Pentolinium.
TramadolThe risk or severity of adverse effects can be increased when Pentolinium is combined with Tramadol.
TrandolaprilTrandolapril may increase the hypotensive activities of Pentolinium.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Pentolinium.
TranylcypromineTranylcypromine may increase the hypotensive activities of Pentolinium.
TravoprostTravoprost may increase the hypotensive activities of Pentolinium.
TreprostinilTreprostinil may increase the hypotensive activities of Pentolinium.
TrichlorfonThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Trichlorfon.
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Pentolinium.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Pentolinium.
TrimazosinPentolinium may increase the hypotensive activities of Trimazosin.
TrimethaphanPentolinium may increase the hypotensive activities of Trimethaphan.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Pentolinium.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Pentolinium.
TubocurarineThe risk or severity of adverse effects can be increased when Pentolinium is combined with Tubocurarine.
UdenafilUdenafil may increase the antihypertensive activities of Pentolinium.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Pentolinium.
UmeclidiniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Umeclidinium.
UnoprostonePentolinium may increase the hypotensive activities of Unoprostone.
ValsartanValsartan may increase the hypotensive activities of Pentolinium.
VardenafilVardenafil may increase the antihypertensive activities of Pentolinium.
VecuroniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Vecuronium.
XylometazolinePentolinium may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Pentolinium.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor binding
Specific Function:
Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding may induce an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is permeable to a range of divalent cations including calcium, the influx of which may activate a potassium current which hyperpolarizes t...
Gene Name:
CHRNA10
Uniprot ID:
Q9GZZ6
Molecular Weight:
49704.295 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. McKay DB, Burkman AM: Nicotinic and nonnicotinic receptor-mediated actions of vinblastine. Proc Soc Exp Biol Med. 1993 Jul;203(3):372-6. [PubMed:8516349 ]
  4. Cachelin AB, Rust G: Beta-subunits co-determine the sensitivity of rat neuronal nicotinic receptors to antagonists. Pflugers Arch. 1995 Jan;429(3):449-51. [PubMed:7761270 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Ligand-gated ion channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRNA3
Uniprot ID:
P32297
Molecular Weight:
57479.54 Da
References
  1. Cachelin AB, Rust G: Beta-subunits co-determine the sensitivity of rat neuronal nicotinic receptors to antagonists. Pflugers Arch. 1995 Jan;429(3):449-51. [PubMed:7761270 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Ligand-gated ion channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRNB4
Uniprot ID:
P30926
Molecular Weight:
56378.985 Da
References
  1. Cachelin AB, Rust G: Beta-subunits co-determine the sensitivity of rat neuronal nicotinic receptors to antagonists. Pflugers Arch. 1995 Jan;429(3):449-51. [PubMed:7761270 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23